ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1100

Citrullinated Antigen-Specific B Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis: Identification and Phenotypic Characterization

Priscilla Kerkman1, Ellen I.H. van der Voort1, Arnaud Zaldumbide2, Emeline Fabre1, Yoann Rombouts1, Theo Rispens3, Gertjan Wolbink4, Rob Hoeben2, Hergen Spits5, Dominique Baeten6, T. W. J. Huizinga1, René E. M. Toes1 and Hans Ulrich Scherer1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands, 3Sanquin Research, Amsterdam, Netherlands, 4Immunopathology, Sanquin Research, Amsterdam, Netherlands, 5Department of Cell Biology and Histology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 6Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: anti-CCP antibodies, auto-immunity and rheumatoid arthritis (RA), B cells

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: B cell Biology and Targets in Rheumatolid Arthritis and other Autoimmune Disease Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of anti-citrullinated protein antibodies (ACPA) in the majority of patients. ACPA represent highly disease-specific biomarkers that predict disease onset in patients with arthralgia. Experimental data suggest that ACPA could be involved in disease pathogenesis. Of interest, however, depletion of CD20+B cells is effective in reducing disease activity, while ACPA serum titres remain rather stable. Also, interference with plasma cell development seems clinically ineffective. Therefore, we hypothesized that ACPA could be surrogate markers for a (potentially pathogenic) auto-reactive B cell response and set out to identify citrullinated antigen-specific B cells in peripheral blood and synovial fluid of patients with RA.

Methods: We generated differentially labelled streptavidin and extravidin tetramers conjugated to biotinylated CCP2 or control antigens to identify citrullinated antigen-specific B cells in peripheral blood and synovial fluid by flow cytometry. Blocking and fluorescence activated cell sorting experiments followed by in-vitro stimulation and culture were used to confirm specificity of the staining approach. Cells were further phenotypically characterized by flow cytometry.

Results: The combination of differentially labelled CCP2 and control tetramers allowed the  successful separation of ACPA-expressing B cells from non-specific background signals. Tetramer-positive B cells, but not tetramer-negative cells, produced large amounts of ACPA upon stimulation. Interestingly, phenotypic analysis revealed that citrullinated antigen-specific B cells are mainly class-switched, post-germinal centre memory B cells and plasma blasts/cells expressing IgG or IgA. Only few cells exhibited a naïve phenotype. We observed a remarkably high frequency of memory B cells (up to 1 in 500) in peripheral blood, which correlated with ACPA serum titres and spontaneous ACPA production in culture.

Conclusion: We developed a novel technology that identifies ACPA-expressing B cells in peripheral blood and synovial fluid of patients with RA, providing the basis for a detailed characterisation of this immune response on a single cell level. First analyses show the presence of a high frequency of memory B cells, which is remarkable considering the continuous presence of citrullinated antigens. These data pave the path for a detailed understanding of the development and maintenance of citrullinated antigen-reactive B cells and could lead to the identification of targets for novel therapeutic interventions.


Disclosure: P. Kerkman, None; E. I. H. van der Voort, None; A. Zaldumbide, None; E. Fabre, None; Y. Rombouts, None; T. Rispens, None; G. Wolbink, Pfizer Inc, 2,Pfizer Inc, 5,Amgen, 5,AbbVie, 5,UCB, 5,BMS, 5; R. Hoeben, None; H. Spits, AIMM Therapeutics, 3; D. Baeten, None; T. W. J. Huizinga, None; R. E. M. Toes, None; H. U. Scherer, None.

To cite this abstract in AMA style:

Kerkman P, van der Voort EIH, Zaldumbide A, Fabre E, Rombouts Y, Rispens T, Wolbink G, Hoeben R, Spits H, Baeten D, Huizinga TWJ, Toes REM, Scherer HU. Citrullinated Antigen-Specific B Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis: Identification and Phenotypic Characterization [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/citrullinated-antigen-specific-b-cells-in-peripheral-blood-and-synovial-fluid-of-patients-with-rheumatoid-arthritis-identification-and-phenotypic-characterization/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/citrullinated-antigen-specific-b-cells-in-peripheral-blood-and-synovial-fluid-of-patients-with-rheumatoid-arthritis-identification-and-phenotypic-characterization/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology